Applied Genetic Technologies Corporation – NASDAQ:AGTC

Add to watchlist

$0.394

Market closed

Open in 2 days

-4.85%

month

-1.75%

quarter

-80.87%

year

Market Cap	N/A
Enterprise value	N/A

P/E	-0.26
EV/Sales	-18.98
EV/EBITDA	0.09
Price/Sales	54.53
Price/Book	0.60
PEG ratio	N/A
EPS	-1.58

Revenue	N/A
EBITDA	-65.74M
Income	-69.43M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-21213.23%
Oper. margin	-20361.54%
Gross margin	0%
EBIT margin	-20361.54%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Applied Genetic Technologies Corporation (NASDAQ:AGTC): Profit margin
Sep 2021	0	-17.11M
Dec 2021	0	-18.43M
Mar 2022	0	-14.90M
Jun 2022	325K	-18.97M	-5837.54%

Applied Genetic Technologies Corporation (NASDAQ:AGTC): Earnings per share (EPS)
2022-02-14	-0.38	-0.45
2022-05-16	-0.43	-0.33
2022-09-27	-0.34	-0.36

Applied Genetic Technologies Corporation (NASDAQ:AGTC): Debt to assets
Dec 2021	92370000	40.88M	44.26%
Mar 2022	87191000	40.16M	46.06%
Jun 2022	66684000	37.20M	55.8%
Sep 2022	57333000	39.68M	69.22%

Applied Genetic Technologies Corporation (NASDAQ:AGTC): Cash Flow
Sep 2021	-15.93M	1.38M	14K
Dec 2021	0	1.04M	164K
Mar 2022	-13.99M	-202K	9.27M
Jun 2022	-18.25M	-860K	-2.36M

Applied Genetic Technologies alternative data

Applied Genetic Technologies
Employees

Applied Genetic Technologies Corporation (NASDAQ:AGTC): Employee count
Aug 2023	102
Sep 2023	102
Oct 2023	102
Nov 2023	102
Dec 2023	102
Jan 2024	102
Feb 2024	102
Mar 2024	102
Apr 2024	102
May 2024	102
Jun 2024	102
Jul 2024	102

Applied Genetic Technologies
Insider Trading

Applied Genetic Technologies Corporation (NASDAQ:AGTC): Insider trades (number of shares)
Period	Buy	Sel
Feb 2022	0	9950
May 2022	0	3994
Jul 2022	0	8070

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	1 Jul 2022	POTTER STEPHEN W officer: Chief Bu..	Common Stock	8,070	$0.78	$6,254
Sale	27 May 2022	REYNOLDS GERALD ANTHONY officer: Chief Accounting Officer officer: Chief Accounting Officer	Common Stock	3,994	$0.85	$3,375
Option	18 Feb 2022	WASHER SUSAN B. director, officer..	Stock Option (right to buy)	120,686	$0.35	$42,240
Sale	18 Feb 2022	WASHER SUSAN B. director, officer..	Common Stock	9,950	$2.18	$21,691
Option	18 Feb 2022	WASHER SUSAN B. director, officer..	Common Stock	120,686	$0.35	$42,240
Option	1 Nov 2021	WASHER SUSAN B. director, officer..	Stock Option (right to buy)	3,877	$3.5	$13,570
Option	1 Nov 2021	WASHER SUSAN B. director, officer..	Common Stock	3,877	$3.5	$13,570
Sale	26 Dec 2019	KROL PATRICK JOHAN HENDRIK 10 percent owner 10 percent owner	Common Stock	81,162	$5.24	$425,289
Purchase	19 Nov 2019	KROL PATRICK JOHAN HENDRIK 10 percent owner 10 percent owner	Common Stock	2,544	$2.79	$7,098
Option	18 Sep 2019	WASHER SUSAN B. director, officer..	Stock Option (right to buy)	5,700	$3.5	$19,950

AGTC insider trading transactions

Applied Genetic Technologies
Patents

Status	Patent	Filling date	Issue date
Application	Application RECOMBINANT AAV PRODUCTION IN MAMMALIAN CELLS Filling date: 15 Mar 2021 Issue date: 4 Nov 2021	15 Mar 2021	4 Nov 2021
Application	Application CODON OPTIMIZED NUCLEIC ACID ENCODING A RETINITIS PIGMENTOSA GTPASE REGULATOR (RPGR) Filling date: 9 Sep 2020 Issue date: 10 Jun 2021	9 Sep 2020	10 Jun 2021
Application	Application PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS, AND METHODS FOR THE TREATMENT OF ACHROMATOPSIA AND OTHER DISEASES Filling date: 1 Dec 2020 Issue date: 27 May 2021	1 Dec 2020	27 May 2021
Application	Application TRIPLE FUNCTION ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF C9ORF72 ASSOCIATED DISEASES Filling date: 22 Oct 2020 Issue date: 20 May 2021	22 Oct 2020	20 May 2021
Application	Application ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR TREATMENT OF PROGRANULIN ASSOCIATED NEURODEGENERATIVE DISEASES OR DISORDERS Filling date: 22 Oct 2020 Issue date: 20 May 2021	22 Oct 2020	20 May 2021
Application	Application ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES AND DISORDERS Filling date: 22 Oct 2020 Issue date: 29 Apr 2021	22 Oct 2020	29 Apr 2021
Application	Application FORMULATION OPTIMIZATION FOR VIRAL PARTICLES Filling date: 5 Jun 2020 Issue date: 29 Apr 2021	5 Jun 2020	29 Apr 2021
Application	Application ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR TREATMENT OF GENETIC HEARING LOSS Filling date: 30 Sep 2020 Issue date: 1 Apr 2021	30 Sep 2020	1 Apr 2021
Application	Application CODON OPTIMIZED NUCLEIC ACID ENCODING A RETINITIS PIGMENTOSA GTPASE REGULATOR (RPGR) Filling date: 22 Oct 2018 Issue date: 12 Sep 2019	22 Oct 2018	12 Sep 2019

AGTC patents

Applied Genetic Technologies
Earnings Call Transcripts

Quarter	Transcript
Q2 2022 14 Feb 2022	Q2 2022 Earnings Call Transcript
Q1 2022 9 Nov 2021	Q1 2022 Earnings Call Transcript
Q4 2021 23 Sep 2021	Q4 2021 Earnings Call Transcript
Q3 2021 17 May 2021	Q3 2021 Earnings Call Transcript

AGTC earnings call transcripts

Applied Genetic Technologies
Executives

Insider	Age	Since	Compensation
Ms. Susan B. Washer (1961) Pres, Chief Executive Officer & Director	64		$788,550
Mr. Stephen W. Potter (1956) Vice President & Chief Bus. Officer	69		$492,170

Applied Genetic Technologies
Latest News

Tuesday, 25 October 2022
08:29	Make Money With Penny Stocks in November? 3 Methods to Use	PennyStocks
Thursday, 1 September 2022
08:00	AGTC to Participate in Upcoming Investor Conferences	GlobeNewsWire
Monday, 1 August 2022
16:05	AGTC to Participate in Upcoming Investor Conferences	GlobeNewsWire
Thursday, 7 July 2022
08:00	AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting	GlobeNewsWire
Tuesday, 8 March 2022
16:05	AGTC to Participate in Upcoming Investor Conferences	GlobeNewsWire
Monday, 14 February 2022
13:01	Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Monday, 7 February 2022
08:00	AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022	GlobeNewsWire
Tuesday, 9 November 2021
09:56	Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates	Zacks Investment Research
Tuesday, 19 October 2021
08:00	AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit	GlobeNewsWire
Thursday, 14 October 2021
17:00	AGTC Announces Two Key Leadership Team Appointments	GlobeNewsWire
Tuesday, 12 October 2021
11:08	AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa	GlobeNewsWire
Monday, 27 September 2021
08:00	AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference	GlobeNewsWire
Friday, 24 September 2021
09:59	Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial	Benzinga
Thursday, 23 September 2021
22:38	Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
16:05	AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021	GlobeNewsWire
Tuesday, 7 September 2021
10:23	AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference	GlobeNewsWire
Thursday, 2 September 2021
09:41	AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference	GlobeNewsWire
Tuesday, 24 August 2021
08:00	Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community	GlobeNewsWire
Thursday, 19 August 2021
16:05	AGTC Announces Sponsorship of Achroma Corp's No Roadblocks Program	GlobeNewsWire
Wednesday, 18 August 2021
08:00	AGTC Appoints Ophthalmology and Retinal Disease Specialist and Industry R&D Veteran Yehia Hashad, MD to its Board of Directors	GlobeNewsWire
Monday, 16 August 2021
08:00	AGTC to Participate in Envision Virtual Conference East 2021 Panel Discussion	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 15 Jul 2021

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Frequently Asked Questions (FAQ)

What's the price of Applied Genetic Technologies stock today?

One share of Applied Genetic Technologies stock can currently be purchased for approximately $0.39.
When is Applied Genetic Technologies's next earnings date?

Unfortunately, Applied Genetic Technologies's (AGTC) next earnings date is currently unknown.
Does Applied Genetic Technologies pay dividends?

No, Applied Genetic Technologies does not pay dividends.
What is Applied Genetic Technologies's stock symbol?

Applied Genetic Technologies Corporation is traded on the NASDAQ under the ticker symbol "AGTC".
What is Applied Genetic Technologies's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Applied Genetic Technologies?

Shares of Applied Genetic Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Applied Genetic Technologies's key executives?
Applied Genetic Technologies's management team includes the following people:
- Ms. Susan B. Washer Pres, Chief Executive Officer & Director(age: 64, pay: $788,550)
- Mr. Stephen W. Potter Vice President & Chief Bus. Officer(age: 69, pay: $492,170)
How many employees does Applied Genetic Technologies have?

As Jul 2024, Applied Genetic Technologies employs 102 workers.
When Applied Genetic Technologies went public?

Applied Genetic Technologies Corporation is publicly traded company for more then 11 years since IPO on 27 Mar 2014.
What is Applied Genetic Technologies's official website?

The official website for Applied Genetic Technologies is agtc.com.
Where are Applied Genetic Technologies's headquarters?

Applied Genetic Technologies is headquartered at 14193 Nw 119Th Terrace, Suite #10, Alachua, FLORIDA.
How can i contact Applied Genetic Technologies?

Applied Genetic Technologies's mailing address is 14193 Nw 119Th Terrace, Suite #10, Alachua, FLORIDA and company can be reached via phone at +1 386 462 2204.

Applied Genetic Technologies Corporation

agtc.com

Exchange:

NASDAQ

Full time employees:

102

Industry:

Biotechnology

Sector:

Healthcare

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

+1 386 462 2204

14193 Nw 119Th Terrace, Suite #10
Alachua, FLORIDA 32615

CIK: 0001273636
ISIN: US03820J1007
CUSIP: 03820J100